title: IRAK1: oncotarget in MDS and AML.
authors.affiliation: Department of Cancer and Cell Biology, University of Cincinnati, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
authors.forename: Levil J
authors.initials: LJ
authors.lastname: Beverly
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Starczynowski
mesh_terms: D000814:Aniline Compounds / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002461:Cell Line, Transformed; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D053592:Interleukin-1 Receptor-Associated Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; C507768:IRAK1 protein, human; D053592:Interleukin-1 Receptor-Associated Kinases; C528561:navitoclax